title: Once-daily, high-concentration MMX mesalamine in active ulcerative colitis.
abstract: OBJECTIVE
  SPD476 (LIALDA in the US; MEZAVANT in the EU; otherwise known as MMX mesalamine; Shire Pharmaceuticals Inc., Wayne, PA, under license from Giuliani SpA, Milan, Italy) is a novel, once-daily, high-strength (1.2 g/tablet) formulation of mesalamine, utilizing MMX Multi Matrix System (MMX) technology designed to deliver the active drug throughout the colon. We performed a double-blind, multicenter study, comparing MMX mesalamine vs placebo for the treatment of active ulcerative colitis. A delayed-release oral mesalamine (ASACOL; Procter & Gamble, Cincinnati, OH) reference arm was included.
  
  
  METHODS
  Three hundred forty-three patients with active, mild-to-moderate ulcerative colitis received MMX mesalamine 2.4 g/day or 4.8 g/day given once daily, ASACOL 2.4 g/day given in 3 divided doses, or placebo for 8 weeks. The primary end point was the proportion of patients in clinical and endoscopic remission (modified ulcerative colitis disease activity index of < or =1 with rectal bleeding and stool frequency scores of 0, no mucosal friability, and a > or =1-point reduction in sigmoidoscopy score from baseline).
  
  
  RESULTS
  A significantly greater proportion of patients receiving MMX mesalamine 2.4 g/day given once daily (40.5%; P = .01) and 4.8 g/day given once daily (41.2%; P = .007) achieved clinical and endoscopic remission at week 8, vs placebo (22.1%). The clinical and endoscopic remission rate for ASACOL (32.6%; P = .124) was not significantly superior to placebo. All active treatments were well-tolerated.
  
  
  CONCLUSIONS
  Once-daily MMX mesalamine was efficacious and well-tolerated for the induction of clinical and endoscopic remission. MMX mesalamine offers effective and convenient mesalamine therapy, potentially improving treatment compliance.
authors.affiliation: Department of Gastroenterology, St. Mark's Hospital, Watford Road, Harrow, United Kingdom. m.kamm@imperial.ac.uk
authors.forename: Michael A
authors.initials: MA
authors.lastname: Kamm
authors.forename: William J
authors.initials: WJ
authors.lastname: Sandborn
authors.forename: Miguel
authors.initials: M
authors.lastname: Gassull
authors.forename: Stefan
authors.initials: S
authors.lastname: Schreiber
authors.forename: Lechoslaw
authors.initials: L
authors.lastname: Jackowski
authors.forename: Todd
authors.initials: T
authors.lastname: Butler
authors.forename: Andrew
authors.initials: A
authors.lastname: Lyne
authors.forename: David
authors.initials: D
authors.lastname: Stephenson
authors.forename: Mary
authors.initials: M
authors.lastname: Palmen
authors.forename: Raymond E
authors.initials: RE
authors.lastname: Joseph
mesh_terms: D000284:Administration, Oral; D000328:Adult; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000008:administration & dosage* / Q000009:adverse effects; D003093:Colitis, Ulcerative / Q000188:drug therapy* / Q000473:pathology; D003692:Delayed-Action Preparations; D004502:Education, Medical, Continuing; D016099:Endoscopy, Gastrointestinal; D005260:Female; D006801:Humans; D008297:Male; D019804:Mesalamine / Q000008:administration & dosage* / Q000009:adverse effects; D008875:Middle Aged; D010349:Patient Compliance; D012074:Remission Induction; D016896:Treatment Outcome
chemical_list: D000894:Anti-Inflammatory Agents, Non-Steroidal; D003692:Delayed-Action Preparations; D019804:Mesalamine